• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Fresenius Medical Care AG

    6/5/25 9:49:29 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care
    Get the next $FMS alert in real time by email
    6-K 1 tm2517263d1_6k.htm FORM 6-K

     

     

     

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

     

    Pursuant to Rule 13a-16 or 15d-16 of the

    Securities Exchange Act of 1934

     

    For the month of June 2025

     

    Commission file number: 001-32749

     

    FRESENIUS MEDICAL CARE AG

    (Translation of registrant's name into English)

     

    Else-Kröner Strasse 1

    61346 Bad Homburg

    Germany

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x            Form 40-F ¨

     

     

     

     

     

     

    EXHIBITS

     

    The following exhibits are being furnished with this Report:

     

    Exhibit 99.1 Press Release issued on June 4, 2025.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    DATE: June 5, 2025

     

      Fresenius Medical Care AG
         
      By: /s/ Helen Giza
      Name: Helen Giza
      Title: Chief Executive Officer and Chair of the Management Board

     

      By: /s/ Martin Fischer
      Name: Martin Fischer
      Title: Chief Financial Officer and member of the Management Board

     

     

     

    Get the next $FMS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FMS

    DatePrice TargetRatingAnalyst
    12/2/2024Underperform → Neutral
    BofA Securities
    11/6/2024$25.60Buy
    Berenberg
    1/8/2024Equal-Weight → Underweight
    Morgan Stanley
    11/24/2023Reduce → Hold
    HSBC Securities
    11/17/2023Hold → Buy
    Societe Generale
    8/14/2023Buy → Neutral
    UBS
    8/1/2023Neutral
    Citigroup
    7/12/2023Buy
    Goldman
    More analyst ratings

    $FMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fresenius Medical upgraded by BofA Securities

      BofA Securities upgraded Fresenius Medical from Underperform to Neutral

      12/2/24 8:51:34 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Berenberg initiated coverage on Fresenius Medical with a new price target

      Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60

      11/6/24 6:26:23 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical downgraded by Morgan Stanley

      Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight

      1/8/24 7:47:44 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico

      High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in MexicoIn Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treatedFresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United StatesBAD HOMBURG, Germany, July 3, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, will extend High-Volume Hemodiafiltration (HighVolumeHDF) access for patients in seven out of 10 centers in Mexico, by partnering with the country's Coordination of National Institu

      7/3/25 8:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

      FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovationThe Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plansProfitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 marginsFME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovationFurther optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0xCommitment to return excess capital to shareholders: 30-40 percent d

      6/17/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.

      Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) ClearanceCompany announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering  high-volume hemodiafiltration therapy to dialysis patientsIntroducing the 5008X CAREsystem and hemodiafiltration kidney replacement therapy is a key pillar of the company's growth strategyBAD HOMBURG, Germany, June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The compa

      6/4/25 8:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    SEC Filings

    See more
    • SEC Form 11-K filed by Fresenius Medical Care AG

      11-K - Fresenius Medical Care AG (0001333141) (Filer)

      6/27/25 1:51:36 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      6/17/25 3:18:39 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      6/5/25 9:49:29 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

      Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

      3/13/24 10:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

      BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in Germany.   Fresenius Medical Care succ

      2/5/24 8:57:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

      Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal formSeveral advantages including faster and more agile decision-makingMichael Sen elected as Chair of new Supervisory BoardConversion expected to be completed by the end of 2023WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a

      7/14/23 11:34:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Financials

    Live finance-specific insights

    See more
    • Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

      FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovationThe Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plansProfitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 marginsFME25+ savings target expanded by EUR 300 million to EUR 1.05 billion by 2027Annual capex of EUR 0.8 to 1.0 billion for core business to drive profitable growth and to support innovationFurther optimization of capital structure with lowered net leverage ratio target band of 2.5x to 3.0xCommitment to return excess capital to shareholders: 30-40 percent d

      6/17/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History

      Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's historyExcellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growthIn 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlookThe company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent marginBAD HOMBURG, Germany, May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading pro

      5/22/25 11:45:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care starts 2025 with strong organic revenue and income growth

      Strong organic revenue growth1 of 5% driven by Care Enablement and Care DeliveryStable U.S. same market treatment development despite impact from a severe flu seasonFME25 savings of EUR 68 million contributed to earningsOperating income2 grew 11% at constant currency resulting in margin expansionReported operating income grew by 35% and reported net income3 by 113%Net leverage ratio further improved to 2.8x and FY 2025 outlook confirmedBAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Ch

      5/6/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fresenius Medical Care AG

      SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

      11/14/24 4:08:53 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

      SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)

      2/13/24 1:36:58 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Fresenius Medical Care AG (Amendment)

      SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)

      12/7/23 11:45:52 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care